Erica Jordan - Feb 27, 2024 Form 3 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role
Chief Commercial Officer
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Stock symbol
RVNC
Transactions as of
Feb 27, 2024
Transactions value $
$0
Form type
3
Date filed
2/29/2024, 04:36 PM
Next filing
Apr 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding RVNC Common Stock 117K Feb 27, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RVNC Performance Stock Units Feb 27, 2024 Common Stock 120K $0.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The performance-based restricted stock units (PSUs) granted to the reporting person on January 31, 2024 represent the right to receive, following vesting, a number of shares of Common Stock up to 150% of the number of PSUs. The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metric, as approved by the Company's Compensation Committee, over a four-year performance period, subject to time based service requirements and continuous employment with the Company through the vesting dates.
F2 The number of securities reported represents the maximum shares that can be earned.

Remarks:

Exhibit 24, Power of Attorney, is attached.